Drug intelligence / Profile preview

BRC-Liver

Development stage: Preclinical
Lead developer: Britecyte
Modality: Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies
Administration: Subcutaneous

Overview

BRC-Liver (also known as BRC001) is an investigational, off-the-shelf, allogeneic engineered adipose formulation under development by Britecyte for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The therapy is composed of a combination of culture-expanded adipose-derived stromal vascular fraction (SVF) cells (mesenchymal stem cells) and adipose tissue particulates. BRC-Liver is designed to address the root cause of MASH by targeting and restoring disrupted metabolism in the patient's white adipose tissue (WAT), thereby reducing hepatic inflammation and liver fibrosis. The program is currently in preclinical development.

Other names: engineered adipose formulationhuman adipose formulation

Beyond the preview

Go deeper on BRC-Liver.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRC-Liver.